Sharemaestro Newsreel

bioAffinity Technologies closes $4 million private placement of pre-funded warrants priced at $0.47

bioAffinity Technologies has successfully closed a private placement, raising approximately $4 million in gross proceeds from pre-funded warrants. The placement involved 8,462,027 common shares, with each pre-funded warrant priced at $0.47 and accompanied by two additional warrants. WallachBeth Capital acted as the sole placement …

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform

iRhythm Holdings,Inc. IRTC recently announced that it will acquire Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. The transaction is expected to expand iRhythm's addressable market and accelerate its evolution from ambulatory cardiac monitoring into a broader cardiac monitoring …

Notable ETF Outflow Detected - SPSM, CORT, GKOS, EAT

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM) where we have detected an approximate $125.1 million dollar outflow -- that's a 0.7% decrease …

Rallybio Corporation (NASDAQ:RLYB) Sees Large Drop in Short Interest

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …

Can NVST Sustain Its 2026 Guidance Boost as Margins Keep Expanding?

Envista Holdings Corporation NVST raised its 2026 outlook after a stronger first half, putting greater emphasis on whether recent sales and profit gains can carry through the rest of the year. Higher revenue expectations and expanding margins support the earnings recovery. China pricing changes, …

Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …

T. Rowe Price Associates (MDWD) discloses 5.0% ownership in Mediwound common stock

T. Rowe Price Associates has reported a 5.0% beneficial ownership in Mediwound Ltd. common stock, totaling 641,075 shares as of June 30, 2026. The firm holds sole voting power over 638,398 shares and sole dispositive power over all 641,075 shares, with no shared voting …

Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Form 8K PAVmed Inc For: 14 August By Investing.com

This article from Investing.com is a regulatory filing notification, specifically a Form 8K for PAVmed Inc. The brief content indicates that the filing was made on August 14th and the article itself was published on the same date. The article is very short and …

Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% of Imunon, Inc.'s common stock, totaling 450,315 shares. This stake is held through Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager and Steven Boyd as its …

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

Sell Alert: Daniel Woolson Cashes Out $982K In ICU Medical Stock

Daniel Woolson, VP at ICU Medical (NASDAQ: ICUI), recently sold 5,417 shares of the company's stock for a total transaction value of $982,264, as disclosed in an SEC filing. This insider transaction occurred on August 13, leading to a slight dip in ICU Medical's …

Armistice Capital (OFIX) discloses 3.26M-share, 8.01% Orthofix Medical stake

Armistice Capital, LLC and Steven Boyd have reported an updated beneficial ownership stake of 8.01% in Orthofix Medical Inc., totaling 3,264,000 shares. This disclosure, made via an Amendment No. 8 to their Schedule 13G, indicates shared voting and dispositive power over these shares, which …

Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside

Sana Biotechnology, Inc.'s average 12-month price target has been reduced slightly from $9.5 to $9.38 by 8 analysts, with individual forecasts ranging from $6 to $16 per share. Despite the cut, the new target still suggests a significant 155% potential upside based on the …

Armistice Capital (RPID) discloses 3.33M-share position in Rapid Micro Biosystems

Armistice Capital, LLC and Steven Boyd have disclosed a 7.29% stake in Rapid Micro Biosystems, Inc. (RPID), amounting to 3,328,000 shares of Class A common stock. All voting and dispositive power over these shares is shared, with Armistice Capital acting as the investment manager …

Aveanna Healthcare (NASDAQ:AVAH) Shares Gap Up Following Better-Than-Expected Earnings

Aveanna Healthcare (AVAH) shares gapped up after reporting better-than-expected earnings, with revenue rising 13.7% year over year to $670.5 million and adjusted EPS of $0.22, surpassing analyst estimates. The company also raised its 2026 guidance, projecting revenue above $2.68 billion and adjusted EBITDA above …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Mobia Medical, Inc. - Common Stock MOBI

Mobia Medical, Inc. (NASDAQ:MOBI) reported strong second-quarter results with revenue reaching $13.5 million, marking a 102% increase year-over-year. This growth is attributed to the expanded adoption of its Vivistim paired vagus nerve stimulation therapy within stroke-care programs.

Heartflow (NASDAQ:HTFL) Shares Gap Up Following Better-Than-Expected Earnings

Heartflow (NASDAQ:HTFL) shares gapped up after reporting better-than-expected earnings, with an adjusted EPS of $(0.07) against estimates of $(0.22) and quarterly revenue of $64.08 million, up 47.7% year over year. The stock opened significantly higher at $39.06 and traded near $41.07, surpassing the analyst …

Heartflow Inc stock hits all-time high at 41.25 USD

Heartflow Inc. stock reached an all-time high of $41.25, reflecting strong investor confidence and recent market momentum, despite InvestingPro's analysis suggesting it may be overvalued. The company reported better-than-expected Q2 2026 results with significant revenue growth, though it remains unprofitable. Stifel raised its price …

Armistice Capital reports 9.99% ownership of Tenon Medical (TNON) through Master Fund

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Tenon Medical, Inc. (TNON) through Armistice Capital Master Fund Ltd. This ownership, totaling 54,554 shares, grants them shared voting and dispositive power. The filing specifies that the Master Fund retains …

Femasys (FEMY) gains Rosalind-linked holder with potential 9.99% equity stake

Investment entities affiliated with Rosalind Advisors Inc. have reported a potential beneficial ownership of up to 9.99% in Femasys Inc. (FEMY) common shares. This stake includes 723,377 common shares and an additional 3,964,123 shares issuable upon warrant exercise, though blocker provisions cap the effective …

Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate

Quince Therapeutics (NASDAQ: QNCX) significantly beat Q2 2026 EPS estimates with a loss of $(12.31) against a consensus of $(26.32), marking an 81.9% improvement year-over-year. The company completed its acquisition of Orphai Therapeutics and raised $115 million in a private placement, strengthening its cash …

CLASS ACTION DEADLINE MONDAY NIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly concerning its pen needle …

ImmuCell Q2 2026 slides: revenue gains offset by margin pressure

ImmuCell (NASDAQ:ICCC) reported mixed Q2 2026 results, with product sales up 11.5% to $7.2 million, but gross margin significantly compressed from 43.7% to 33.9%. Despite a tripling of net income to $1.8 million largely due to a $2 million legal settlement, the stock dropped …

ImmuCell Corporation - Common Stock ICCC

ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased …

Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 1,889,366 common shares of Fennec Pharmaceuticals Inc. (FENC), representing a 5.4% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing. The ownership is held through a private …

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position

Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is …

T. Rowe Price (RVTY) reports 16.4% Revvity stake, 18.3M shares under control

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 18,269,089 shares of Revvity Inc. common stock, which accounts for 16.4% of the outstanding class. The firm holds sole voting power over 17,089,376 shares and sole dispositive power over all 18,269,089 shares. …

Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore

Woodline Partners discloses 8.1% CalciMedica (CALC) stake and sole voting power

Woodline Partners LP has reported a beneficial ownership of 8.1% in CalciMedica, Inc., totaling 2,489,729 shares of common stock. The investment firm, acting as an adviser to Woodline Master Fund LP, holds sole voting and dispositive power over these shares. This disclosure, made via …

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company

Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other …

GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened …